Key result
Selective KATP openers match first-generation agents for cardioprotection with less vasorelaxation in animal ischemia models.
Why the study?
KATP openers have demonstrated cardioprotective effects but their use is limited by complications such as coronary steal and hypotension, necessitating development of safer agents.
Do selective KATP openers provide cardioprotection with fewer vasorelaxant side effects in myocardial ischemia?
Do selective KATP openers provide cardioprotection with fewer vasorelaxant side effects in myocardial ischemia?
Selective KATP openers like BMS-180448 may offer a higher margin of safety for cardioprotection during myocardial ischemia by minimizing hypotensive and coronary steal effects.
Answers are grounded in this paper and cite their sources.
Requires careful risk-benefit assessment before clinical cardioprotection; leaves open safer KATP modulators in human ischemia models.
ATP-sensitive potassium channel (KATP) openers are potent antihypertensive agents due to their peripheral vasodilating properties. Although KATP openers have been shown to be direct cardioprotective agents, they carry a certain degree of liability for their use as cardioprotective agents. Their potent coronary and peripheral vasodilating properties can cause complications such as coronary artery steal and hypotension resulting in underperfusion of the tissue already at risk. Also, cardioprotection is not related to action potential shortening and the development of agents devoid of this activity would be desirable. Recent studies indicate that the beneficial effects of myocardial preconditioning might be mediated via opening of the KATP· Therefore, the opening of KATP might constitute an endogenous protective mechanism used by the heart under ischemic stress. Development of therapeutics to mimic this powerful protective mechanism is an attractive approach for the discovery of myocardial protecting agents. In this review, we describe the progress made towards understanding the cardioprotective properties of KATP openers including the discovery of agents that might offer a higher margin of safety for the treatment of myocardial ischemia with this class of agents. We found distinct structure-activity relationships for the cardioprotective and vasorelaxant potencies of KATP openers. Based on the structure-activity relationship studies, we were able to find cardioprotective KATP openers (BMS- 180448) which, despite being equipotent to the first generation agents (e.g., cromakalim) as cardioprotectants, had lower vasorelaxant potencies. The cardioprotecti ve effects of these selective KA TP openers in animal models of myocardial ischemia-reperfusion are also discussed in this review.
No takes yet. Share an insight, caveat, or question.
Atwal et al. (1996) conducted a review in Myocardial Ischemia. ATP-Sensitive Potassium Channel (KATP) Openers vs. First generation agents (e.g., cromakalim) was evaluated. Selective KATP openers like BMS-180448 demonstrated equipotent cardioprotective effects with lower vasorelaxant potencies compared to first-generation agents in animal models of myocardial ischemia.
Synapse has enriched 10 related papers. Consider them for comparative context: